MP CARDIOFLOW-B (02160) surged more than 10% again. At the time of writing, the stock was up 8.7%, trading at HK$1.25, with a turnover of HK$11.48 million.

The company recently announced that its VitaFlow series transcatheter aortic valve and delivery system has now entered 35 countries and regions globally, with cumulative implants nearing 1,300 cases.

Specifically, the implant volume for 2025 is projected to exceed 850 cases, representing a surge of nearly 350% compared to 2024.

Furthermore, the implant volume in the second half of 2025 grew by over 170% compared to the first half.

Notably, on December 21, the company announced the completion of a strategic merger with MicroPort Cardiac Rhythm Management.

CITIC Securities stated that through the strategic integration of MicroPort's cardiac rhythm management business, the company has broken its reliance on the single structural heart disease segment, significantly enhancing its risk resilience.

Concurrently, MP CARDIOFLOW gains access to a more mature global sales network, which will further accelerate its overseas market expansion.

Looking ahead, MP CARDIOFLOW is poised to leverage the combined R&D and technological expertise of both entities in the medical device field to build a global specialized platform for heart failure diagnosis and treatment devices.